Trial Profile
An Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of PUL-042 Inhalation Solution in Subjects With Hematologic Malignancies and Recipients of Stem Cell Transplantation
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs ODN/Pam2 (Primary)
- Indications Pneumocystis pneumonia
- Focus Therapeutic Use
- Sponsors Pulmotect
- 25 Apr 2023 Planned End Date changed from 1 May 2025 to 1 May 2026.
- 25 Apr 2023 Planned primary completion date changed from 1 Mar 2025 to 1 Mar 2026.
- 25 Apr 2023 Planned initiation date changed from 1 Dec 2023 to 1 Dec 2024.